Premenstrual Dysphoric Disorder

At the initial visit, directly assess suicidal ideation, intent, plan, prior attempts, psychosis, mania or hypomania, substance use, and inability to maintain safety. Suicidal ideation or significant psychiatric distress requires prompt mental-health evaluation and safety intervention; prospective charting is used to confirm cyclicity, not to defer acute care. PubMedPubMedPremenstrual Disorders - StatPearls - NCBI Bookshelf - NIH

A retrospective history can justify a provisional PMDD diagnosis and initial symptom-directed treatment, but it does not establish the diagnosis. Ask the patient to identify the first day of bleeding, symptom-free days, use of hormonal contraception, and whether clinically important depression, anxiety, irritability, or interpersonal dysfunction persists outside the luteal phase. Prospective daily ratings across at least 2 consecutive symptomatic cycles must confirm the diagnosis. PubMed+2PubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedPremenstrual Disorders - Abstract - Europe PMCPubMedTable 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf

Review drugs and exposures that can produce mood symptoms, and assess medical alternatives when indicated by history or examination. DSM-based criteria require that symptoms not be attributable to a substance, medication, other treatment, or medical disorder; hyperthyroidism is a named alternative medical explanation. PubMed+1PubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedTable 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf

Use the Daily Record of Severity of Problems (DRSP) each day for at least 2 consecutive symptomatic cycles. The DRSP includes 24 items: 21 items spanning 11 symptom domains and 3 items addressing functional impairment; each item is rated from 1, not at all, to 6, extreme. This prospective record is more reliable than retrospective symptom recall and establishes timing, severity, and functional consequences. PubMed+1PubMedMaking Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder - PMCPubMedPremenstrual Disorders - StatPearls - NCBI Bookshelf - NIH

Confirm DSM-pattern timing: symptoms occur in the final week before menses, improve within a few days after menstrual bleeding begins, and become minimal or absent in the week after menses. Symptoms must be present in most menstrual cycles over the preceding year, although prospective two-cycle documentation is the required confirmation step. PubMed+1PubMedPremenstrual Disorders - Abstract - Europe PMCPubMedTable 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf

Require at least 5 of 11 symptoms, including at least 1 core affective symptom: affective lability, irritability or anger, depressed mood or hopelessness, or anxiety or tension. Additional qualifying symptoms include diminished interest, concentration difficulty, low energy, appetite change, sleep disturbance, feeling overwhelmed or out of control, and physical symptoms. The symptoms must cause clinically significant distress or impairment in work, school, social activities, or relationships. PubMed+1PubMedPremenstrual Disorders - Abstract - Europe PMCPubMedTable 1, Diagnostic Criteria for Premenstrual Dysphoric Disorder (PMDD) - Endotext - NCBI Bookshelf

Premenstrual exacerbation is worsening of an existing psychiatric disorder before menses, whereas PMDD requires a distinct cyclical pattern with symptoms minimal or absent after menses. Major depressive disorder, persistent depressive disorder, panic disorder, anxiety disorders, and personality disorders can coexist with PMDD but cannot be relabeled PMDD if the diary shows substantial symptoms throughout the cycle. PubMed+1PubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedPremenstrual Disorders - Abstract - Europe PMC

Use daily ratings to compare premenstrual symptom burden with the postmenstrual week rather than relying on a report that symptoms are “worse before the period.” In research applying C-PASS, clinically significant PME was operationalized as at least a 30% premenstrual increase relative to the postmenstrual week for an emotional symptom; this quantifies worsening but does not substitute for the full PMDD diagnostic pattern. PubMedPubMedPerimenstrual Exacerbation of Symptoms in Borderline Personality Disorder: Evidence from Multilevel Models and the Carolina Premenstrual Assessment Scoring System

In patients with borderline personality disorder, daily DRSP data may reveal meaningful premenstrual elevations in depression, anxiety, anger, rejection sensitivity, or interpersonal conflict. This pattern should prompt treatment of the baseline personality disorder and risk assessment in addition to cycle-specific interventions; it should not be assumed to represent PMDD without the required symptom-free interval and full criteria. PubMed+2PubMedPerimenstrual Exacerbation of Symptoms in Borderline Personality Disorder: Evidence from Multilevel Models and the Carolina Premenstrual Assessment Scoring SystemPubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedPremenstrual Disorders - Abstract - Europe PMC

Offer an SSRI as first-line pharmacotherapy when mood symptoms or functional impairment are clinically significant. Fluoxetine, sertraline, and paroxetine are the SSRIs identified as FDA-approved in the United States for severe PMS/PMDD. SSRIs have rapid PMDD symptom effects, reported within 1 to 2 days, permitting either continuous administration or treatment confined to the luteal phase. publications aap+1publications aapMenstrual Disorders | AAP Books | American Academy of PediatricsccjmPremenstrual dysphoric disorder: A review for the treating ...

Select continuous SSRI dosing when symptoms extend beyond the luteal phase, when PME or another depressive or anxiety disorder is present, or when a patient prefers a consistent regimen. Luteal-phase dosing, typically begun 10 to 14 days before anticipated menses, can reduce medication exposure and adverse effects for patients with a clearly limited premenstrual symptom window. A 2024 Cochrane review of 34 randomized trials concluded that SSRIs reduce PMDD symptoms and that continuous dosing may be more effective than intermittent dosing. Wolters Kluwer+1Wolters KluwerEvaluation and management of premenstrual dysphoric disorder ...ccjmPremenstrual dysphoric disorder: A review for the treating ...

Before prescribing, discuss nausea, insomnia, fatigue, nervousness, headache, and sexual dysfunction. Reassess daily ratings, adverse effects, adherence, functional impairment, and suicidal thinking after treatment initiation; use the same prospective instrument to determine whether the premenstrual symptom peak and impairment have diminished. PubMed+1PubMedPremenstrual Disorders - StatPearls - NCBI Bookshelf - NIHccjmPremenstrual dysphoric disorder: A review for the treating ...

For patients who desire contraception and do not have contraindications to combined hormonal contraception, a drospirenone-containing combined oral contraceptive is a reasonable hormonal option. Hormonal effects on mood are not uniform: some individuals improve while others worsen, so establish a baseline diary and reassess after initiation rather than presuming a class-wide psychiatric effect. Nature+1NaturePremenstrual Syndrome and Dysphoric Disorder Management | Psychiatry | Clinical Sciences | Health sciences | Topics | Nature IndexNatureThe impact of ovulation-suppressing contraceptives on behavioral and functional difficulties in borderline personality disorder | Neuropsychopharmacology

Before labeling PMDD refractory, review the prospective diary for a true postmenstrual remission, determine whether the apparent failure is actually PME or an untreated baseline disorder, and verify the treatment schedule and tolerability. This reassessment matters because diagnostic overlap with depression, anxiety, bipolar disorder, and personality disorders is common. Nature+2NaturePremenstrual dysphoric disorder in online peer support communities: a Reddit case study | Scientific ReportsPubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedPremenstrual Disorders - Abstract - Europe PMC

Gonadotropin-releasing hormone agonists suppress ovulation and usually decrease PMDD symptoms; they are a hormonal suppression option for refractory illness rather than routine initial therapy. Their use should follow confirmation of a cycle-linked disorder and a careful discussion of the consequences of abolishing ovarian hormone fluctuations and the safety implications of longer-term hormonal suppression. Nature+2NaturePremenstrual Syndrome and Dysphoric Disorder Management | Psychiatry | Clinical Sciences | Health sciences | Topics | Nature Indexema europa eu[PDF] Guideline on the treatment of Premenstrual Dysphoric Disorder ...ccjmWomen and headache: A treatment approach based on life ...

Refer patients with persistent severe impairment, uncertain bipolar-spectrum illness, suicidal symptoms, complex psychiatric comorbidity, or failure of SSRI and contraceptive-based strategies to clinicians with reproductive psychiatry and gynecology expertise. The referral question should specify whether the diary demonstrates PMDD, PME, or both, because that distinction determines whether continuous psychiatric treatment, hormonal suppression, or combined care is needed. Nature+2NaturePremenstrual dysphoric disorder in online peer support communities: a Reddit case study | Scientific ReportsPubMedDiagnostic validity of premenstrual dysphoric disorder: revisitedPubMedPremenstrual Disorders - Abstract - Europe PMC